logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

NSCLC: pepinemab-avelumab combo provides disease control in phase 2

The combination was well-tolerated in interim analysis of CLASSICAL-Lung trial.